I’m using Warren Buffett’s advice and buying these dirt-cheap tech stocks

Warren Buffett hasn’t traditionally been a fan of tech stocks. But these two are trading in significant value territory and I’m following his advice and buying.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Fans of Warren Buffett taking his photo

Image source: The Motley Fool

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

In the past, Warren Buffett has not been overly keen on investing in tech stocks, due to his preference for value stocks. However, Buffett has also advised investors to “be fearful when others are greedy, and greedy when others are fearful”. Right now, there is a lot of fear around growth stocks, due to high rates of inflation and rising interest rates. But this potentially makes now an ideal time to buy. Here are two companies I feel Warren Buffett might be particularly interested in. 

A cheap biotechnology stock

AbCellera Biologics (NASDAQ: ABCL) is a biotechnology firms that researches and develops antibodies. However, the stock has continued to fall and over the last 12 months it has sunk around 70%. This seems entirely detached from the company’s performance. 

For example, in 2021, AbCellera reported revenues of $375m, an increase of 61% year-on-year. This also converted into strong profits as net earnings reached $153m, up from $119m the year before. From a valuation perspective, this puts AbCellera on a price-to-earnings ratio of around 16. For a biotechnology company that’s seeing growth, this seems very cheap, and might appeal to Warren Buffett.

But there are some reasons why AbCellera trades on a low P/E ratio. For example, the reason why profits have been so large recently is the company’s development of bamlanivimab, which has been used as a coronavirus treatment, in partnership with Eli Lilly. This has contributed towards the majority of AbCellera revenues and earnings over the past couple of years. 

But even with coronavirus becoming less prominent, I’m still confident about the future of AbCellera. For instance, at the end of 2021, the company had 156 programmes under contract (a 51% year-on-year rise) and five programmes in the clinic (compared to just one the year before). This may explain why there has been significant amounts of insider buying recently, which is another bullish sign. Therefore, I feel that now that it’s beaten-down, Warren Buffett would be tempted to buy this stock. I’m also keen, and am tempted to add more AbCellera shares to my portfolio.

A fintech with the quality Warren Buffett requires 

Warren Buffett only buys quality companies and after years of outperformance, PayPal (NYSE: PYPL) is, I feel, such a business. Its recent Q1 results continued to demonstrate the firm’s dominance in the fintech space. Revenues rose 8% year-on-year to $6.5bn and total payment volume grew 15% to $323bn. Unlike other growth stocks such as Netflix, PayPal was able to continue growing users, seeing an increase of 2.4m accounts in Q1. 

Nonetheless, while these results were positive, they do still show that growth is slowing considerably. For example, revenues for 2022 are ‘only’ expected to rise around 12%, compared to 17% the year before. 

But after the share price has fallen 65% in the past year, I feel this has been factored in. Indeed, PayPal now has a P/E ratio of just 30, far lower than it has been historically. This represents the value Warren Buffett looks for. Further, the company’s subsidiary Venmo, continues to grow rapidly, and a tie-up with Amazon, to be implemented later in the year, should progress this growth further. As such, with a reasonable valuation, and its continued dominance in the fintech space, I’ll continue to buy PayPal stock. 

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Stuart Blair owns shares in AbCellera Biologics and PayPal Holdings. The Motley Fool UK has recommended PayPal Holdings. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »